Atopic Dermatitis Clinical Trials 2022
Atopic Dermatitis studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect atopic dermatitis clinical trial in 2022.
Condition
Atopic Dermatitis
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Atopic Dermatitis Clinical Trials 2022
1
Effectiveness
2
Safety
RPT193
for Eczema, Infantile
Cypress, TX
18+
All Sexes
Phase 2
Recruiting
Cypress, TX
18+
All Sexes
Phase 2 study of RPT193 in adults with atopic dermatitis
2
Effectiveness
3
Safety
AMG 451
for Eczema
Plainfield, IN
18+
All Sexes
Phase 3
Recruiting
Plainfield, IN
18+
All Sexes
The purpose of this study is to evaluate the efficacy and safety of AMG 451 in monotherapy treatment.
1
Effectiveness
1
Safety
BBI-02 Capsule
for Dermatitis, Dermatitis Atopic
Montréal, Canada
18 - 65
All Sexes
Phase 1
Recruiting
Montréal, Canada
18 - 65
All Sexes
BBI-02 is an orally-available, potent and selective DYRK1A inhibitor.
1
Effectiveness
1
Safety
Dupilumab
for Dermatitis
Scottsdale, AZ
18 - 65
All Sexes
Phase < 1
Recruiting
Scottsdale, AZ
18 - 65
All Sexes
The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.
1
Effectiveness
2
Safety
ASLAN004
for Eczema
Dallas, TX
18+
All Sexes
Phase 2
Recruiting
Dallas, TX
18+
All Sexes
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).
1
Effectiveness
2
Safety
AK120
for Eczema, Infantile
Rapid City, SD
18+
All Sexes
Phase 2
Waitlist Available
Rapid City, SD
18+
All Sexes
This study is evaluating whether a drug called dupilumab can help treat atopic dermatitis.
1
Effectiveness
1
Safety
Ruxolitinib Cream
for Dermatitis, Dermatitis Atopic
Miami, FL
< 18
All Sexes
Phase 1
Recruiting
Miami, FL
< 18
All Sexes
This study is evaluating whether a drug called ruxolitinib can be used to treat atopic dermatitis in children.
2
Effectiveness
3
Safety
Tapinarof Cream, 1%
for Eczema, Infantile
Huntington Beach, CA
Any Age
All Sexes
Phase 3
Recruiting
Huntington Beach, CA
Any Age
All Sexes
This study is evaluating whether a cream can improve the symptoms of atopic dermatitis.
1
Effectiveness
2
Safety
Branebrutinib
for Dermatitis
Verdun, Communauté-Urbaine-de-Montréal, Canada
18+
All Sexes
Phase 2
Recruiting
Verdun, Communauté-Urbaine-de-Montréal, Canada
18+
All Sexes
This study is evaluating whether a drug called branebrutinib can help treat atopic dermatitis.
1
Effectiveness
1
Safety
GSK1070806
for Dermatitis
London, Canada
18+
All Sexes
Phase 1
Recruiting
London, Canada
18+
All Sexes
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
2
Effectiveness
3
Safety
Core Treatment Active Experimental: SHR0302 Dose#2
for Eczema, Infantile
Toronto, Canada
Any Age
All Sexes
Phase 3
Waitlist Available
Toronto, Canada
Any Age
All Sexes
This study is evaluating whether a drug called dupilumab can help treat atopic dermatitis.
1
Effectiveness
2
Safety
CC-93538
for Eczema, Infantile
Oakville, Canada
18+
All Sexes
Phase 2
Waitlist Available
Oakville, Canada
18+
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
1
Effectiveness
1
Safety
Cream IP
for Dermatitis
Lynchburg, VA
< 18
All Sexes
Recruiting
Lynchburg, VA
< 18
All Sexes
This study is evaluating whether a new cream may help improve eczema symptoms in children.
1
Effectiveness
2
Safety
Benralizumab
for Dermatitis
Bridgeport, CT
Any Age
All Sexes
Phase 2
Waitlist Available
Bridgeport, CT
Any Age
All Sexes
This study is evaluating whether a drug may help reduce the symptoms of asthma.
2
Effectiveness
3
Safety
Lebrikizumab
for Eczema
New Orleans, LA
Any Age
All Sexes
Phase 3
Recruiting
New Orleans, LA
Any Age
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
1
Effectiveness
2
Safety
Nemolizumab
for Eczema, Infantile
Troy, MI
< 65
All Sexes
Phase 2
Recruiting
Troy, MI
< 65
All Sexes
This study is evaluating whether a drug may help improve the immune response to vaccines in individuals with atopic dermatitis.
1
Effectiveness
2
Safety
MEDI3506
for Eczema, Infantile
Spartanburg, SC
18+
All Sexes
Phase 2
Waitlist Available
Spartanburg, SC
18+
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
2
Effectiveness
3
Safety
Nemolizumab
for Eczema, Infantile
Hialeah, FL
Any Age
All Sexes
Phase 3
Waitlist Available
Hialeah, FL
Any Age
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
3
Effectiveness
3
Safety
Dupilumab
for Dermatitis
San Francisco, CA
18+
All Sexes
Phase 4
Waitlist Available
San Francisco, CA
18+
All Sexes
This study is evaluating whether dupilumab may have positive impacts for individuals with atopic dermatitis.
1
Effectiveness
1
Safety
Upadacitinib (ABT-494)
for Eczema, Infantile
Hershey, PA
< 18
All Sexes
Phase 1
Recruiting
Hershey, PA
< 18
All Sexes
This study is evaluating whether a drug may help treat severe atopic dermatitis in children.
2
Effectiveness
3
Safety
Abrocitinib 200 Mg
for Eczema, Infantile
Columbus, GA
Any Age
All Sexes
Phase 3
Waitlist Available
Columbus, GA
Any Age
All Sexes
This study is evaluating whether a drug called Abrocitinib can help treat atopic dermatitis.
1
Effectiveness
1
Safety
RVT-501 0.5% Topical Ointment
for Eczema
Irvine, CA
< 18
All Sexes
Phase 1
Waitlist Available
Irvine, CA
< 18
All Sexes
This is a multicenter, open-label Phase 1b study in pediatric patients age 2-11 years old with extensive atopic dermatitis.
3
Effectiveness
3
Safety
Dupilumab
for Eczema, Infantile
San Francisco, CA
18+
All Sexes
Phase 4
Recruiting
San Francisco, CA
18+
All Sexes
This study is evaluating whether dupilumab may have positive impacts for individuals with atopic dermatitis.
3
Effectiveness
3
Safety
Dupixent
for Dermatitis, Dermatitis Atopic
East Windsor, NJ
18+
All Sexes
Phase 4
Waitlist Available
East Windsor, NJ
18+
All Sexes
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
1
Effectiveness
2
Safety
Tapinarof Cream, 1%
for Eczema
Hialeah, FL
< 18
All Sexes
Phase 2
Recruiting
Hialeah, FL
< 18
All Sexes
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
1
Effectiveness
2
Safety
Ruxolitinib Cream
for Dermatitis
Culver City, CA
Any Age
All Sexes
Phase 2
Recruiting
Culver City, CA
Any Age
All Sexes
This study is evaluating whether a cream can improve the symptoms of atopic dermatitis.
1
Effectiveness
2
Safety
EDP1815
for Eczema, Infantile
Concord, OH
18+
All Sexes
Phase 2
Recruiting
Concord, OH
18+
All Sexes
This study is evaluating whether a drug can improve the symptoms of atopic dermatitis.
1
Effectiveness
2
Safety
LEO 152020 Tablet
for Dermatitis
Mississauga, Canada
18+
All Sexes
Phase 2
Recruiting
Mississauga, Canada
18+
All Sexes
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it works to treat AD and what the side effects are when compared with a placebo tablet with no medical ingredient. During the study, there will be a 16-week treatment period during which the participants will be asked to take the tablets. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms, itch, sleep, and quality of life.
1
Effectiveness
2
Safety
Rilzabrutinib
for Eczema, Infantile
Louisville, KY
18+
All Sexes
Phase 2
Recruiting
Louisville, KY
18+
All Sexes
This study is evaluating whether a new drug can help treat atopic dermatitis.
1
Effectiveness
2
Safety
PRN473 (SAR444727)
for Eczema, Infantile
Houston, TX
18+
All Sexes
Phase 2
Recruiting
Houston, TX
18+
All Sexes
This study is evaluating whether a drug called PRN473 can improve the symptoms of Alzheimer's disease.
2
Effectiveness
3
Safety
Ruxolitinib
for Eczema, Infantile
Detroit, MI
< 18
All Sexes
Phase 3
Recruiting
Detroit, MI
< 18
All Sexes
This study is evaluating whether a cream containing a drug called ruxolitinib can improve the symptoms of atopic dermatitis in children.
1
Effectiveness
2
Safety
Nemolizumab
for Eczema, Infantile
San Antonio, TX
< 18
All Sexes
Phase 2
Recruiting
San Antonio, TX
< 18
All Sexes
This study is evaluating whether a drug called nemolizumab can help treat atopic dermatitis in children.
2
Effectiveness
3
Safety
ARQ-151 Active
for Eczema, Infantile
Rockville, MD
< 18
All Sexes
Phase 3
Recruiting
Rockville, MD
< 18
All Sexes
This study is evaluating whether a cream may help treat atopic dermatitis.
2
Effectiveness
3
Safety
ARQ-151 Active
for Eczema, Infantile
Arlington, TX
Any Age
All Sexes
Phase 3
Recruiting
Arlington, TX
Any Age
All Sexes
This study is evaluating whether a cream may help treat atopic dermatitis.
1
Effectiveness
1
Safety
KT-474
for Eczema, Infantile
Fair Lawn, NJ
18 - 65
All Sexes
Phase 1
Recruiting
Fair Lawn, NJ
18 - 65
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis or hidradenitis suppurativa.
2
Effectiveness
3
Safety
Lebrikizumab
for Eczema, Infantile
Savannah, GA
18 - 65
All Sexes
Phase 3
Recruiting
Savannah, GA
18 - 65
All Sexes
This study is evaluating whether a drug may help improve the immune response to vaccines in individuals with atopic dermatitis.
1
Effectiveness
2
Safety
Naltrexone
for Eczema, Infantile
Minneapolis, MN
18+
All Sexes
Phase 2
Waitlist Available
Minneapolis, MN
18+
All Sexes
This study is evaluating whether a specific gene may be related to chronic itch.
1
Effectiveness
1
Safety
1.1% W/w AMTX-100 CF
for Dermatitis
Philadelphia, PA
18+
All Sexes
Phase 1 & 2
Waitlist Available
Philadelphia, PA
18+
All Sexes
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates efficacy of various concentrations of AMTX-100 CF versus placebo (vehicle). The study has two parts: Phase I (Part 1): Approximately Twenty five (25) subjects with various treatable Body Surface Area (BSA) involvement of Mild to Moderate Atopic Dermatitis will be enrolled in the study and treated with 1.1% w/w AMTX-100 CF. Phase II (Part 2): Approximately One Hundred Twenty (120) subjects with Mild to Moderate Atopic Dermatitis with various treatable BSA involvement of Mild to Moderate Atopic Dermatitis will be randomized to be treated with different concentrations of AMTX-100 CF (low concentration (0.11% w/w), medium concentration (0.33% w/w) and high concentration (1.1% w/w)) or Vehicle (Placebo) in the study.
2
Effectiveness
3
Safety
Lebrikizumab
for Dermatitis
Saint Joseph, MI
< 18
All Sexes
Phase 3
Waitlist Available
Saint Joseph, MI
< 18
All Sexes
This study is evaluating whether a drug may help treat moderate to severe atopic dermatitis.
2
Effectiveness
3
Safety
Lebrikizumab
for Dermatitis
Bellaire, TX
Any Age
All Sexes
Phase 3
Waitlist Available
Bellaire, TX
Any Age
All Sexes
This study is evaluating whether a drug called lebrikizumab is safe and effective for treating atopic dermatitis.
2
Effectiveness
3
Safety
Nemolizumab
for Eczema, Infantile
Santa Monica, CA
Any Age
All Sexes
Phase 3
Recruiting
Santa Monica, CA
Any Age
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
1
Effectiveness
2
Safety
ALX-101 Gel 5%
for Dermatitis
Marietta, GA
Any Age
All Sexes
Phase 2
Waitlist Available
Marietta, GA
Any Age
All Sexes
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis
2
Effectiveness
3
Safety
Tralokinumab
for Eczema, Infantile
Miami, FL
Any Age
All Sexes
Phase 3
Waitlist Available
Miami, FL
Any Age
All Sexes
This study is evaluating whether a drug called tralokinumab is safe to use over a long period of time.
2
Effectiveness
3
Safety
Upadacitinib
for Eczema, Infantile
Montréal, Canada
Any Age
All Sexes
Phase 3
Waitlist Available
Montréal, Canada
Any Age
All Sexes
This study is evaluating whether a drug called upadacitinib can help treat people with moderate to severe atopic dermatitis.
1
Effectiveness
2
Safety
PR022
for Eczema
Philadelphia, PA
18+
All Sexes
Phase 2
Waitlist Available
Philadelphia, PA
18+
All Sexes
The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
2
Effectiveness
3
Safety
Dupilumab
for Eczema, Infantile
Centennial, CO
< 18
All Sexes
Phase 3
Waitlist Available
Centennial, CO
< 18
All Sexes
This study is evaluating the long-term safety of dupilumab in pediatric participants with AD.
1
Effectiveness
1
Safety
Electronic Reminders
for Dermatitis
Vancouver, Canada
< 18
All Sexes
Waitlist Available
Vancouver, Canada
< 18
All Sexes
Forgetting is usually listed as the most important cause of low adherence among patients. Most studies to date have looked at the adherence of adults or adolescent population. No studies have been done looking specifically at adherence to topical treatment by parents/caregivers of young children. Our project will try to replicate the same results among the parents/caregivers responsible for children ten years and under. The population in this study will be the parents/caregivers of children 10 and under with atopic dermatitis and the intervention will be the effect of electronic reminders in adherence rates for the use of a moisturizer which is recognized as part of the standard of care in the treatment of atopic dermatitis.
1
Effectiveness
1
Safety
UCB1381
for Eczema, Infantile
Glendale, CA
18+
All Sexes
Phase 1 & 2
Recruiting
Glendale, CA
18+
All Sexes
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
3
Effectiveness
3
Safety
Reflectance Confocal Microscopy
for Eczema
New York, NY
18+
All Sexes
Phase 4
Recruiting
New York, NY
18+
All Sexes
The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"
3
Effectiveness
3
Safety
Dupilumab
for Moderate to Severe Atopic Dermatitis
Chicago, IL
< 18
All Sexes
Phase 4
Recruiting
Chicago, IL
< 18
All Sexes
Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).
2
Effectiveness
3
Safety
Tralokinumab
for Eczema, Infantile
Dallas, TX
Any Age
All Sexes
Phase 3
Recruiting
Dallas, TX
Any Age
All Sexes
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection with Device A in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
2
Effectiveness
3
Safety
Tapinarof Cream, 1%
for Eczema
Pinellas Park, FL
Any Age
All Sexes
Phase 3
Recruiting
Pinellas Park, FL
Any Age
All Sexes
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
1
Effectiveness
2
Safety
KY1005
for Dermatitis, Dermatitis Atopic
Markham, Canada
18+
All Sexes
Phase 2
Recruiting
Markham, Canada
18+
All Sexes
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the LTE protocol at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.
3
Effectiveness
3
Safety
Dupilumab
for Eczema
Chicago, IL
< 18
All Sexes
Phase 4
Recruiting
Chicago, IL
< 18
All Sexes
This study is evaluating whether dupilumab can improve sleep, pruritus and circadian function in children.
2
Effectiveness
3
Safety
Tapinarof Cream, 1%
for Eczema, Infantile
Gresham, OR
Any Age
All Sexes
Phase 3
Recruiting
Gresham, OR
Any Age
All Sexes
This study is evaluating whether a cream can help treat atopic dermatitis.
1
Effectiveness
2
Safety
Ruxolitinib Cream
for Dermatitis
Montreal, Canada
18+
All Sexes
Phase 2
Recruiting
Montreal, Canada
18+
All Sexes
This study is evaluating whether a cream can help reduce itch in people with atopic dermatitis.
3
Effectiveness
3
Safety
Dupilumab SAR231893
for Eczema, Infantile
Miami, FL
18+
All Sexes
Phase 4
Waitlist Available
Miami, FL
18+
All Sexes
Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus Secondary Objectives: Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus To evaluate the efficacy of dupilumab in AD participants with chronic pruritus To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD
2
Effectiveness
3
Safety
ARQ-151 Cream 0.15% Or ARQ-151 Cream 0.05%
for Eczema
West Lafayette, IN
Any Age
All Sexes
Phase 3
Recruiting
West Lafayette, IN
Any Age
All Sexes
This study is evaluating whether a cream may help treat atopic dermatitis.
1
Effectiveness
2
Safety
CYP 450 Substrates
for Eczema, Infantile
North Hollywood, CA
18+
All Sexes
Phase 2
Recruiting
North Hollywood, CA
18+
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
1
Effectiveness
1
Safety
AD Educational Videos
for Eczema
Boston, MA
< 18
All Sexes
Recruiting
Boston, MA
< 18
All Sexes
The primary objective of this randomized trial is to determine whether comprehensive, accessible, and animation-style videos are a more effective method of therapeutic patient education (TPE) based on clinical outcomes than paper handouts in Spanish and English-speaking communities. The clinical outcomes being measured are the severity, sleep affected by atopic dermatitis (AD), and the amount of itch experienced.
2
Effectiveness
3
Safety
Upadacitinib
for Dermatitis
Surrey, Canada
18+
All Sexes
Phase 3
Waitlist Available
Surrey, Canada
18+
All Sexes
This study is evaluating whether a drug called Upadacitinib is safe and effective for people with moderate to severe atopic dermatitis.
2
Effectiveness
3
Safety
Nemolizumab
for Eczema, Infantile
Ann Arbor, MI
Any Age
All Sexes
Phase 3
Waitlist Available
Ann Arbor, MI
Any Age
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
1
Effectiveness
1
Safety
Team-Based Connected Health (TCH)
for Dermatitis
Los Angeles, CA
Any Age
All Sexes
Recruiting
Los Angeles, CA
Any Age
All Sexes
This study is evaluating whether an online approach to managing atopic dermatitis may be as effective as in-person care.
1
Effectiveness
1
Safety
Tencel Therapeutic Garments
for Eczema
Baltimore, MD
< 18
All Sexes
Waitlist Available
1 Prior Treatment
Baltimore, MD
< 18
All Sexes
Approximately 15-20% of children in the United States suffer from the symptoms of atopic dermatitis (eczema), which include pruritus, pain, irritation, and difficulty sleeping. Tencel fabric has been marketed as a superior fabric for children with atopic dermatitis due to improved moisture absorption and decreased bacterial growth compared to cotton and synthetic fabrics. However, no dermatologic studies have been conducted on Tencel fabric. The investigators' objective is to perform a randomized double-blinded trial comparing Tencel garments to traditional cotton for children with moderate to severe atopic dermatitis. The investigators hypothesize that children in the Tencel group will demonstrate improvement in Eczema Area and Severity Index (EASI) scores, Investigator's Global Assessment, pruritus as measured by ItchyQoL: A Pruritus-Specific Quality of Life Instrument, and Children's Dermatology Life Quality Index (CDQLI) or Infant's Dermatitis Quality of Life Index (IDQoL). An randomized double-blind trial of 12 weeks duration will be conducted. Fifty children age 6 months to 6 years with moderate to severe eczema will be recruited from the Johns Hopkins pediatric dermatology clinic and given 6 weeks of standard skin directed therapy followed by 6 weeks during which children will be randomized to treatment with Tencel vs. cotton therapeutic garments in addition to standard eczema care. The primary outcome will be eczema severity as assessed by EASI score by blinded and trained investigators. Secondary outcomes will include patient-reported eczema symptoms (assessed through quality of life and pruritus scales, CDQLI or IDQoL and ItchyQoL scores) and frequency of infection of eczema lesions. Adherence with wearing study garments and usage of standard eczema treatments (topical corticosteroids and calcineurin inhibitors, emollients, and wet/dry wraps) will also be assessed.
2
Effectiveness
3
Safety
Upadacitinib
for Eczema, Infantile
Long Beach, CA
Any Age
All Sexes
Phase 3
Waitlist Available
Long Beach, CA
Any Age
All Sexes
This study is evaluating whether a drug called upadacitinib can help treat Alzheimer's disease.
2
Effectiveness
3
Safety
Topical Corticosteroids (TCS)
for Eczema, Infantile
Bexley, OH
Any Age
All Sexes
Phase 3
Waitlist Available
Bexley, OH
Any Age
All Sexes
This study is evaluating whether a drug called upadacitinib can be used to treat people with moderate to severe atopic dermatitis.
2
Effectiveness
3
Safety
Baricitinib
for Dermatitis
Johnston, RI
18+
All Sexes
Phase 3
Waitlist Available
Johnston, RI
18+
All Sexes
This study is evaluating whether a drug called baricitinib may help treat atopic dermatitis.
1
Effectiveness
1
Safety
Naltrexone
for Dermatitis
Minneapolis, MN
18+
All Sexes
Phase 1
Recruiting
Minneapolis, MN
18+
All Sexes
This study is evaluating whether clonidine or naltrexone are safe and effective for treating atopic dermatitis.
2
Effectiveness
3
Safety
Dupilumab
for Eczema, Infantile
Portsmouth, NH
18+
All Sexes
Phase 3
Waitlist Available
Portsmouth, NH
18+
All Sexes
This study is evaluating whether dupilumab is safe for long-term use in people with atopic dermatitis.
1
Effectiveness
2
Safety
AK002
for Dermatitis
Philadelphia, PA
18+
All Sexes
Phase 2
Recruiting
Philadelphia, PA
18+
All Sexes
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given monthly for 4 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments.
1
Effectiveness
2
Safety
LEO 138559
for Dermatitis
Philadelphia, PA
18 - 65
All Sexes
Phase 2
Waitlist Available
Philadelphia, PA
18 - 65
All Sexes
This study is evaluating whether a new medicine can help treat atopic dermatitis.
3
Effectiveness
3
Safety
Dupilumab SAR231893
for Eczema, Infantile
Denver, CO
< 18
All Sexes
Phase 4
Waitlist Available
Denver, CO
< 18
All Sexes
Primary Objective: - Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric patients with moderate to severe atopic dermatitis (AD) treated with dupilumab Secondary Objectives: Evaluate changes in skin barrier function with TEWL assessed after STS in predefined lesional and non lesional skin in pediatric patients with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. Evaluate time course of change in skin barrier function with TEWL assessed before and after STS in predefined lesional and non-lesional skin in pediatric patients with moderate to severe AD during dupilumab treatment phase and follow-up period in reference to normal skin of healthy volunteers
1
Effectiveness
1
Safety
PF-07242813
for Eczema, Infantile
Tustin, CA
18+
All Sexes
Phase 1
Recruiting
Tustin, CA
18+
All Sexes
This study is evaluating whether PF-07242813 may be a safe and effective treatment for atopic dermatitis.
3
Effectiveness
3
Safety
Crisaborole
for Eczema, Infantile
Chicago, IL
< 18
All Sexes
Phase 4
Recruiting
Chicago, IL
< 18
All Sexes
This study is evaluating whether a skin cell sample can predict which medication will work best for a child with atopic dermatitis.
1
Effectiveness
1
Safety
Standard Clothing
for Eczema, Infantile
Chicago, IL
< 18
All Sexes
Waitlist Available
Chicago, IL
< 18
All Sexes
This study is evaluating whether wool clothing may help reduce the severity of atopic dermatitis.
1
Effectiveness
2
Safety
One-Step Open Feeding
for Eczema, Infantile
Bethesda, MD
< 65
All Sexes
Phase 2
Recruiting
Bethesda, MD
< 65
All Sexes
Background: Atopic dermatitis (AD), also called eczema, makes skin dry, red, and itchy. People with AD are more likely to get a food allergy than people without AD. But some food allergy tests are not always accurate in people with AD. Researchers want to study if people are truly allergic to milk and/or peanuts. Objectives: To improve the ways doctors test for food allergy in people with AD. Eligibility: People ages 3 21 who have had AD; have a high total IgE level (an allergic antibody); might have a milk and/or peanut allergy; and are currently enrolled in another NIH study Design: Participants will be screened under another protocol. Participants will have a physical exam, blood tests, and medical history. Participants will breathe into a plastic device that measures lung strength. Participants may get a small plastic tube inserted in their arm. Participants who have not had an allergic reaction to food in the past 3 years will do 1 or more oral food challenge (OFCs) depending on their allergies. They will eat a little bit of the food they might be allergic to. They will be watched for a reaction. If they have one, they will know for sure they are allergic. They may keep eating bigger portions of the food until they either have a reaction or finish all the food. In some OFCs, participants will get a placebo food. OFCs will last a few hours or 2 days. Participants will repeat all tests at each OFC. Participation can last up to 12 months. ...
1
Effectiveness
2
Safety
ISB 830 - Part 1 Group 1
for Dermatitis
West Des Moines, IA
18+
All Sexes
Phase 2
Waitlist Available
West Des Moines, IA
18+
All Sexes
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 comprising Part 2. All subjects will receive open-label ISB 830 after a 16 week blinded treatment period.
1
Effectiveness
1
Safety
EUCRISA
for Dermatitis
Winston-Salem, NC
< 65
All Sexes
Phase 1
Waitlist Available
Winston-Salem, NC
< 65
All Sexes
This study is evaluating whether a medication can improve the symptoms of atopic dermatitis.
2
Effectiveness
3
Safety
Amino Acid Moisturizing Cream
for Dermatitis
Boston, MA
18+
All Sexes
Phase 3
Waitlist Available
Boston, MA
18+
All Sexes
The purpose of this study is to compare the effects of an amino acid moisturizing cream and desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to moderate atopic dermatitis/eczema.
Other Trials to Consider
Dupilumab
for Dermatitis
1
Effectiveness
1
Safety
Phase < 1
Recruiting
Scottsdale, AZ
18 - 65
All Sexes
BBI-02 Capsule
for Dermatitis, Dermatitis Atopic
1
Effectiveness
1
Safety
Phase 1
Recruiting
Montréal, Canada
18 - 65
All Sexes
Ruxolitinib Cream
for Dermatitis, Dermatitis Atopic
1
Effectiveness
1
Safety
Phase 1
Recruiting
Miami, FL
< 18
All Sexes
AK002
for Dermatitis
1
Effectiveness
2
Safety
Phase 2
Recruiting
Philadelphia, PA
18+
All Sexes
Branebrutinib
for Dermatitis
1
Effectiveness